Skip to main content
. Author manuscript; available in PMC: 2012 Aug 15.
Published in final edited form as: Virology. 2011 Jun 30;417(1):196–202. doi: 10.1016/j.virol.2011.05.014

Fig. 6. Protective efficacy against influenza A/WSN/33 virus.

Fig. 6

Immune sera collected from untreated or low pH treated A/PR8 virus vaccinated mice at 4 weeks after boost vaccination were incubated with a lethal dose of A/WSN/33 (H1N1) influenza virus at room temperature for 30 min. Groups of mice (n=4) were intranasally challenged with a lethal infectious dose (5 LD50) mixed with immune sera. (A-B) 3 fold diluted immune sera were used for incubating with A/WSN/33 virus. Body weight (A) and survival rate (B) were monitored for 14 days. (C-D) 6 fold diluted immune sera were used for incubating with A/WSN/33 virus. Body weight (C) and survival rate (D) were monitored for 14 days. *: p<0.05 at day 7 post infection.